ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Alternative cutoffs for cortisol post-Dexamethasone suppression testing: is there a practical point for the bone health evaluation?
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCurrent guideline-based stratification in the non-secretory adrenal tumors (ADTs) involves the second-day (post-Dexamethasone testing) plasma cortisol (D-C) threshold of <1.8 μg∕dL to determine a non-functional profile and another one for a mild cortisol secretion (cortisol between 1.8 and 5 μg∕dL).
objectiveTo analyze the bone status in terms of mineral metabolism, circulating biomarkers of bone turnover and bone mineral density in menopausal women with ADTs by comparing two population subgroups, according to distinct thresholds for D-C, which are out of the current guidelines (1.4 μg∕dL and 0.9 μg∕dL, respectively). PATIENTS, MATERIALS AND
methodsA retrospective analysis was conducted in ADT-positive menopausal women.
resultsFinal analysis included 109 adults: ADT-1 group (52.3%; D-C: ≤1.4 μg∕dL) vs. ADT-2 group (47.7%; D-C: 1.4-5 μg∕dL) and ADT-3 group (20.2%; D-C: ≤0.9 μg∕dL) vs. ADT-4 group (79.8%; D-C: 0.9-5 μg∕dL), respectively. ADT-1 group vs. ADT-2 group was at similar age (60.14±8.56 vs. 60.08±11.85 years), menopause duration (13.85±7.41 vs. 14.19±8.54 years), body mass index (30.78±6.20 vs. 29.23±6.73 kg∕m²), and obesity rate (56% vs. 35.9%). Mineral metabolism assays showed no between-group difference. Both groups experienced a vitamin D deficiency according to 25-hydroxyvitamin D (23.69±10.42 vs. 25.35±9.98 ng∕mL, p=0.481). Except for femoral neck T-score within ADT-1 group (-1.22±1.11), all the other dual energy X-ray absorptiometry (DXA) categories were normal. The prevalence of osteoporosis diagnosis was similar: 24.5% vs. 35.4%, with lower fracture rate (3.5% compared to 21.2%, p=0.005). ADT-3 group compared to ADT-4 group showed a similar bone health status. Half of patients suffered from obesity (50% vs. 46.4%, p=0.775). A borderline significance was attributed to a higher total hip T-score in ADT-3 group vs. ADT-4 group (-0.23 vs. -0.87, p=0.06), both with intra-normal values, and a lower fracture rate (0% vs. 14.9%, p=0.053). Osteoporosis diagnosis displayed a statistically significant decrease in the prevalence in ADT-3 group vs. ADT-4 group: 5.6% vs. 35.4% (p=0.042).
conclusionsMenopausal adults with D-C >0.9 μg∕dL should be mandatory tested for osteoporosis, and those with D-C >1.4 μg∕dL should be additionally screened for osteoporotic fractures, while age is not different among the subgroups with different cutoffs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.